Dendrimers: novel polymeric nanoarchitectures for solubility enhancement

Biomacromolecules
Umesh GuptaN K Jain

Abstract

Poor solubility and hydrophobicity of drugs/bioactives limit their possible applications in drug delivery and formulation development. Apart from conventional methods of solubility enhancement, there are some novel methods which can be used in solubilization. Dendrimers represent a novel type of polymeric material that has generated much interest in many diverse areas due to their unique structure and properties. Dendrimer-mediated solubility enhancement mainly depends on factors such as generation size, dendrimer concentration, pH, core, temperature, and terminal functionality. Added advantage in solubilization can be achieved considering these factors. Available literature suggests that ionic interaction, hydrogen bonding, and hydrophobic interactions are the possible mechanisms by which a dendrimer exerts its solubilizing property. This review presents various mechanisms and reports relating to solubility enhancement using dendrimers. Also, micellar behavior and future possibilities in relation to solubilization via dendrimers are included.

References

May 1, 1989·Journal of Pharmaceutical Sciences·A R Green, J K Guillory
Jan 1, 1994·Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine·E C WienerP C Lauterbur
Mar 18, 1994·Science·R GrefR Langer
May 14, 1996·Proceedings of the National Academy of Sciences of the United States of America·J F Kukowska-LatalloJ R Baker
Aug 1, 1998·Journal of Controlled Release : Official Journal of the Controlled Release Society·S Y KimY K Sung
Mar 8, 2000·International Journal of Pharmaceutics·O M MilhemA D'Emanuele
Jan 16, 2002·International Journal of Pharmaceutics·Ajay J KhopadeNarendra K Jain
Jul 23, 2002·Current Opinion in Chemical Biology·Anil K PatriJames R Baker
Apr 25, 2003·International Journal of Pharmaceutics·D BhadraN K Jain
Jul 26, 2003·Journal of Controlled Release : Official Journal of the Controlled Release Society·Abhay S ChauhanPrakash V Diwan
Feb 1, 1963·Journal of Pharmaceutical Sciences·V S VENTURELLAR W SAGER
Nov 26, 2003·Journal of Controlled Release : Official Journal of the Controlled Release Society·Tooru OoyaKinam Park
Mar 17, 2004·Journal of Controlled Release : Official Journal of the Controlled Release Society·Antony D'EmanueleDavid Attwood
Sep 30, 2004·International Journal of Pharmaceutics·Bharathi DevarakondaMelgardt M de Villiers
Dec 2, 2004·Journal of the American Chemical Society·Dharma Rao VutukuriS Thayumanavan

❮ Previous
Next ❯

Citations

Dec 25, 2010·Pharmaceutical Research·Wassana WijagkanalanMitsuru Hashida
Apr 11, 2012·Chemical Reviews·Jingjing HuYiyun Cheng
Jun 16, 2012·The Journal of Physical Chemistry. a·Rakhee C Pani, Yaroslava G Yingling
Nov 3, 2011·ACS Nano·Stephen SoukaseneSamuel I Stupp
Feb 13, 2013·Physical Chemistry Chemical Physics : PCCP·Priyanka BhattacharyaPu Chun Ke
Aug 6, 2010·Biological & Pharmaceutical Bulletin·Wen-Jun YaoAi-Ping Wang
Jul 2, 2011·Biological & Pharmaceutical Bulletin·Katarzyna WinnickaElzbieta Tryniszewska
Feb 11, 2012·The Journal of Chemical Physics·M Kosmas, P Efthymiopoulos
Nov 28, 2013·International Journal of Pharmaceutics·Maha NasrAbdelbary Elhissi
Nov 5, 2013·The Journal of Chemical Physics·P M Welch
Sep 27, 2008·Nanomedicine·Sonke Svenson, Abhay S Chauhan
Jul 1, 2009·Future Medicinal Chemistry·Julien OgierEric Doris
Dec 3, 2013·International Journal of Pharmaceutics·Vijay Mishra, N K Jain
Apr 25, 2009·The Journal of Chemical Physics·N K VoulgarakisP M Welch
Apr 1, 2014·Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy·Usharani SubuddhiAshok K Mishra
Apr 8, 2014·Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy·Adam BuczkowskiBartlomiej Palecz
Jul 21, 2011·Journal of Drug Delivery·Lifang ShiGang-Yu Liu
Jul 27, 2014·Colloids and Surfaces. B, Biointerfaces·Deep PoojaRamakrishna Sistla
Aug 6, 2008·Expert Opinion on Drug Metabolism & Toxicology·Narendra K Jain, Umesh Gupta
Dec 22, 2007·Expert Opinion on Drug Delivery·Ben J Boyd
Apr 8, 2010·Drug Development and Industrial Pharmacy·Esra GüçUfuk Gündüz
Jun 16, 2010·Drug Development and Industrial Pharmacy·Wenjun YaoAiping Wang
Jun 19, 2012·Expert Opinion on Drug Delivery·Faiyaz ShakeelIbrahim A Alsarra
Nov 6, 2008·Journal of Drug Targeting·Rakesh Kumar TekadeNarendra Kumar Jain
Dec 10, 2009·Cutaneous and Ocular Toxicology·Hamid R MoghimiMohammad Erfan
Aug 28, 2007·Journal of Pharmaceutical Sciences·Yiyun ChengTongwen Xu
Oct 31, 2012·Colloids and Surfaces. B, Biointerfaces·Guangpu LiuHongxiang Lou
May 10, 2012·International Journal of Pharmaceutics·Lakshmi Narashimhan RamanaUma Maheswari Krishnan
Nov 18, 2011·Colloids and Surfaces. B, Biointerfaces·Guobin DingXuezhong Zhang
Aug 2, 2011·Journal of Controlled Release : Official Journal of the Controlled Release Society·Kai-Ling ChangMitsuru Hashida
Jun 15, 2011·Nanomedicine : Nanotechnology, Biology, and Medicine·Loan HuynhChristine Allen
Feb 15, 2011·Journal of Controlled Release : Official Journal of the Controlled Release Society·Lisa M KaminskasChristopher J H Porter

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.